Background: Aidi injection (ADI)is a Chinese patent medicine with anti-cancer effect, which has been used to treat breast cancer (BC) in China for many years, but its potential pharmacological mechanism is still indeterminacy. In this resaearch, network pharmacology, a systematic and comprehensive approach, was used to reveal ADI's potential pharmacological mechanism in treating BC for the first time.Methods: Databases were used to collect targets related to the bioactive components of ADI and BC. the relevant networks were established by the string database, and were screened potential bioactive components and core targets. Eventually, core targets and pathway enrichment were analyzed by DAVID database.Results: As the results showed, we collected 99 bioactive ingredients,345 ADI-related targets after deduplication and 368 BC-related targets. Of these, 108 common targets were overlapped. We then performed an enrichment analysis on the common target network and the protein-protein interaction (PPI) network.Conclusion: The results showed that ADI may inhibit breast cancer through seven important signal pathways involved in the "regulation of vascular endothelial function", "inflammatory response" and "apoptosis” biological processes. Through further clustering and enrichment analysis of the PPI network of ADI’s bioactive component targets and BC-related targets, we found that cancer, ErbB, MAPK, TLR, chemokine, p53 and cell cycle signaling pathway, mainly contributed to the effects of ADI in treating BC. In conclusion, this study reveals the possible mechanism of ADI in treating BC, and provides a new direction for drug development for ADI in treating BC.